Publications
BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.
Note: To find a complete list of Publications, please see listing here.
Found 151 results
“Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced intensity conditioning HCT. Blood Advances”, Blood Advances, 2023.
, “Cost-Effectiveness of Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Bone Marrow Transplantation: Evidence from BMT CTN 1101.”, Transplant Cell Ther, 2023.
, “Health-Related Quality of Life in Double Umbilical Cord Blood versus Haploidentical Marrow Transplantation: A Quality of Life Analysis Report of BMT CTN 1101.”, Transplant Cell Ther, 2023.
, “How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?”, Blood Rev, p. 101079, 2023.
, “Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy.”, Bone Marrow Transplant, 2023.
, “SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study.”, EClinicalMedicine, vol. 59, p. 101983, 2023.
, “Are We Making PROGRESS in Preventing Graft-versus-Host Disease and Improving Clinical Outcomes? Impact of BMT CTN 1301 Study Results on Clinical Practice.”, Transplant Cell Ther, vol. 28, no. 8, pp. 419-425, 2022.
, “Bringing Patient and Caregivers Voices to the Clinical Trial Chorus: A Report From the BMT CTN Patient and Caregiver Advocacy Task Force.”, Transplant Cell Ther, vol. 29, no. 1, pp. 5-9, 2022.
, “Decoupling blood telomere length from age in recipients of allogeneic hematopoietic cell transplant in the BMT-CTN 1202.”, Front Immunol, vol. 13, p. 966301, 2022.
, “Enrollment Lessons from a Biological Assignment Study of Marrow Transplantation versus Standard Care for Adolescents and Young Adults with Sickle Cell Disease: Considerations for Future Gene and Cellular Therapy Trials.”, Transplant Cell Ther, vol. 29, no. 4, pp. 217-221, 2022.
, “Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.”, Lancet Haematol, 2022.
, “Health-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102.”, Am J Hematol, vol. 98, no. 2, pp. 229-250, 2022.
, “Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012.”, Transplant Cell Ther, vol. 28, no. 7, pp. 406.e1-406.e6, 2022.
, “The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials.”, Transplant Cell Ther, 2022.
, “Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).”, Blood Cancer J, vol. 12, no. 2, p. 27, 2022.
, “A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial.”, Transplant Cell Ther, 2022.
, “Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.”, Transplant Cell Ther, vol. 28, no. 8, pp. 446-454, 2022.
, “Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study.”, Transplant Cell Ther, vol. 29, no. 3, pp. 166.e1-166.e10, 2022.
, “Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.”, Lancet Haematol, vol. 9, no. 5, pp. e374-e384, 2022.
, “Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma.”, Am J Hematol, 2022.
, “Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.”, N Engl J Med, vol. 387, no. 2, pp. 132-147, 2022.
, “Two-sample survival probability curves: A graphical approach for the analysis of time to event data in clinical trials.”, Contemp Clin Trials, vol. 115, p. 106707, 2022.
, “The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.”, Transplant Cell Ther, vol. 27, no. 10, pp. 807-816, 2021.
, “Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study.”, J Clin Oncol, vol. 39, no. 17, pp. 1878-1887, 2021.
, “Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.”, J Clin Oncol, vol. 39, no. 30, pp. 3328-3339, 2021.
,